

## RADIOPHARM SIGNS LOI WITH GENESISCARE TO START FIRST TRIAL IN AUSTRALIA

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has agreed commercial terms for services in a signed Letter of Intent (LOI) with global oncology provider GenesisCare, whose support is critical to start Radiopharm’s first Phase 1 trial in Australia.

The phase 1 therapeutic trial will involve Radiopharm’s proprietary nanobody from its Nano-mAbs platform, which targets the PDL1 expression in non-small cell lung cancer, the most common type of lung cancer. This is an area of high unmet need and there is potential for the treatment to be the “*first in class*” radiopharmaceutical therapy targeting PDL1.

GenesisCare is a leading provider of integrated oncology care globally, with more than 440 locations in Australia, UK, the USA and Spain. GenesisCare’s global innovation programs aim to bring novel therapies and precision medicine to more cancer patients in need to achieve the best possible life outcomes. Radiopharm is excited to be partnering with a provider of GenesisCare’s scale and reputation as the Company embarks on trialling its innovative and promising radiopharmaceutical therapies.

“We are proud to have entered an LOI with GenesisCare, Australia’s largest provider of integrated cancer care, to support a trial for our innovative radiopharmaceutical therapy targeting non-small cell lung cancer, pending ethics approval from Australian authorities. This is currently an area of high unmet need, and we are hopeful of bringing a first in class treatment to the market that will greatly improve patient outcomes. The phase 1 trial is an important milestone on the path to making this a reality,” said Radiopharm’s CEO & Managing Director Riccardo Canevari.

Kris Barooshian, Senior Vice President of Research and Insights at GenesisCare, said “GenesisCare’s Contract Research Organisation and Site Research Organisation are delighted to be partnering with Radiopharm Theranostics on this clinical trial that may bring hope to thousands of Australians living with non-small cell lung cancer.”

“To date, radiopharmaceutical treatments have predominantly been utilised in the treatment of prostate cancer and neuroendocrine tumours, so it is exciting to be expanding the nuclear medicine treatment paradigm to new therapeutic areas,” said Professor Nat Lenzo, GenesisCare Nuclear Medicine Physician and Group Clinical Director of Theranostics.

Whilst the LOI is not a binding agreement, work has already commenced under the LOI. The corresponding services agreement is currently being negotiated. The term of the initial project is anticipated to be 18 months. The overall cost of the services under the LOI are not considered material and are included in existing budgets and funding. Under the LOI, Radiopharm will deploy its novel radiopharmaceutical (RAD204) targeting PDL/1-positive lung cancer in patients at Australian clinical research centres secured by GenesisCare. It is likely that this will be the first-ever human clinical trial exposure to this Radiopharm compound and, if successful, will set the stage for expanded development in lung cancer patients whose cancer is sensitive to treatment with this type of immunotherapy.

**ASX ANNOUNCEMENT  
23 MARCH 2022**



**Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper.**

**For more information:**

Riccardo Canevari  
CEO & Managing Director  
P: +1 862 309 0293  
E: rc@radiopharmtheranostics.com

Paul Hopper  
Executive Chairman  
P: +61 406 671 515  
E: paulhopper@lifescienceportfolio.com

Media

Matt Wright  
NWR Communications  
P: +61 451 896 420  
E: matt@nwrcommunications.com.au

**Follow Radiopharm Theranostics:**

Website – <https://radiopharmtheranostics.com/>  
Twitter – <https://twitter.com/TeamRadiopharm>  
Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>